10-K: NexPoint Capital Inc. Reports Full Year 2023 Results, Portfolio Shifts to Healthcare and Middle-Market Debt

NexPoint Capital Inc.'s 2023 annual report reveals a strategic shift towards middle-market healthcare companies and syndicated floating rate debt, alongside a decrease in net assets.

Summary

• NexPoint Capital Inc., a business development company, released its 2023 annual report, highlighting a focus on generating current income and capital appreciation.
• The company's investment strategy emphasizes middle-market healthcare companies, syndicated floating rate debt, and CLOs.
• As of December 31, 2023, the investment portfolio consisted of 35 positions with a total fair value of $49.4 million.
• The portfolio is allocated across various asset classes, including 20.5% in first lien senior secured loans, 0.3% in second lien senior secured loans, 0.5% in corporate bonds, 0.0% in asset-backed securities, 0.6% in warrants, 32.3% in common stock, 21.0% in preferred stocks and 21.0% in LLC interests.
• The debt investments in the portfolio have a weighted average cost price of 98.09% on par or stated value, with an estimated gross annual portfolio yield of 2.58%.
• The company reported a net increase in net assets resulting from operations of $1.45 million, or $0.17 per share, for the year ended December 31, 2023.
• The company's net assets decreased from $53.7 million in 2022 to $49.8 million in 2023.
• The company's net asset value per share decreased from $5.55 in 2022 to $5.35 in 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is strategically positioned in growing sectors, the decrease in net assets and NAV per share, along with the low portfolio yield and high allocation to Level 3 investments, raise concerns. The document is more negative than positive.

Positives

• The company's investment strategy focuses on high-income generating debt investments and income-generating equity securities.
• The company has a diversified portfolio across various asset classes and industries.
• The company's investment strategy leverages the expertise of the Adviser in healthcare, credit, and structured products.
• The company has a share repurchase program in place to provide liquidity to stockholders.

Negatives

• The company's net assets decreased from $53.7 million in 2022 to $49.8 million in 2023.
• The company's net asset value per share decreased from $5.55 in 2022 to $5.35 in 2023.
• The company's portfolio yield of 2.58% is relatively low.
• The company's portfolio includes a significant portion of Level 3 investments, which are valued using unobservable inputs and are subject to valuation risk.
• The company's portfolio includes investments in distressed debt obligations, which present special tax issues and may be subject to default risk.
• The company's portfolio includes investments in CLOs, which are subject to leverage risk and may be less transparent than direct investments.

Risks

• The company's investments are subject to market risk, credit risk, interest rate risk, and liquidity risk.
• The company's investments in middle-market companies are subject to risks associated with smaller businesses, including limited financial resources and dependence on key personnel.
• The company's investments in the healthcare industry are subject to risks associated with government regulation, competition, and technological changes.
• The company's use of leverage may magnify potential losses.
• The company's dependence on the Adviser for management and investment decisions creates a risk of conflicts of interest.
• The company's ability to achieve its investment objective is dependent on the Adviser's ability to identify and manage investments effectively.
• The company's ability to make distributions to stockholders is dependent on its financial performance and compliance with regulatory requirements.
• The company's investments in foreign securities are subject to risks associated with currency fluctuations, political instability, and less developed markets.
• The company's investments in CLOs are subject to risks associated with leverage, credit quality, and complex structures.
• The company's investments in distressed debt obligations are subject to risks associated with default, bankruptcy, and uncertain tax treatment.

Future Outlook

The company intends to continue to focus on generating current income and capital appreciation through investments in middle-market healthcare companies, syndicated floating rate debt, and CLOs. The company also intends to continue to offer to repurchase shares on a quarterly basis, subject to certain limitations.

Industry Context

The company's focus on middle-market healthcare companies and syndicated floating rate debt aligns with current trends in the investment industry. The healthcare sector is experiencing growth due to demographic shifts and technological advancements, while floating rate debt offers protection against rising interest rates. However, the company faces competition from other public and private funds, commercial banks, and private equity funds.

Comparison to Industry Standards

• The company's portfolio yield of 2.58% is relatively low compared to some other BDCs, which may offer higher yields in exchange for higher risk.
• The company's allocation to Level 3 investments is relatively high compared to some other BDCs, which may indicate a higher level of valuation risk.
• The company's focus on middle-market healthcare companies is a common strategy among BDCs, but the specific companies and investments may vary significantly.
• The company's use of leverage is subject to regulatory limitations and may be lower than some other BDCs that utilize higher levels of leverage to enhance returns.

Related Party Transactions

• The company has entered into an Investment Advisory Agreement and an Administration Agreement with the Adviser, which is controlled by the company's president.
• The company has a dealer manager agreement with NexPoint Securities, Inc., an affiliate of the Adviser.
• The company has an expense limitation agreement with the Adviser, which limits certain expenses to 1.0% of the quarter-end value of the company's gross assets.
• Liberty CLO Holdco Ltd. purchased 2,549,002 shares of the Company from the Adviser.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the decrease in net assets and NAV per share.
• Shareholders may receive distributions that are classified as a return of capital, which is not taxable but reduces their cost basis.
• Shareholders may be subject to tax consequences from the company's investments in foreign securities and derivatives.
• Shareholders may be subject to risks associated with the company's investments in middle-market companies, healthcare companies, and CLOs.
• Shareholders may be subject to risks associated with the company's use of leverage and short-selling strategies.
• Shareholders may be subject to risks associated with the company's reliance on the Adviser for management and investment decisions.

Next Steps

• The company intends to continue to focus on generating current income and capital appreciation through investments in middle-market healthcare companies, syndicated floating rate debt, and CLOs.
• The company intends to continue to offer to repurchase shares on a quarterly basis, subject to certain limitations.

Key Dates

Keywords

Business Development Company, BDC, Middle-Market Companies, Healthcare Investments, Syndicated Loans, Collateralized Loan Obligations, CLOs, Debt Investments, Equity Investments, Floating Rate Debt, Credit Risk, Investment Portfolio, Net Asset Value, Leverage, Distressed Debt